Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Epizyme (NASDAQ: EPZM), Blueprint Medicines (NASDAQ: BPMC) and PTC Therapeutics (NASDAQ: PTCT).
Epizyme (NASDAQ: EPZM)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) on June 15. The company’s shares opened today at $14.80.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.7% and a 56.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.38, representing a 64.7% upside.
In a report issued on June 11, Roth Capital also maintained a Buy rating on the stock with a $26 price target.
See today’s analyst top recommended stocks >>
Blueprint Medicines (NASDAQ: BPMC)
Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Blueprint Medicines (NASDAQ: BPMC) yesterday and set a price target of $105. The company’s shares opened today at $69.44.
According to TipRanks.com, Lee is a 4-star analyst with an average return of 6.9% and a 47.2% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Blueprint Medicines is Strong Buy and the average price target is $105.25, representing a 51.6% upside.
In a report issued on June 2, BTIG also maintained a Buy rating on the stock with a $107 price target.
PTC Therapeutics (NASDAQ: PTCT)
Cowen & Co. analyst Ritu Baral maintained a Hold rating on PTC Therapeutics (NASDAQ: PTCT) yesterday. The company’s shares opened today at $49.54, close to its 52-week high of $52.95.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 37.7% and a 57.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
PTC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $32.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
